{"denoms":[{"counts":[{"groupId":"BG000","value":"14"}],"units":"Participants"}],"groups":[{"description":"Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic \\[related or unrelated\\] Hematopoietic SCT.\n\nPentostatin: 4 mg/m2/24 hour IV continuously over 72 hours on days -8 to -6. Alemtuzumab: 20 mg per dose IV over 8 hours on days -5 to -1. Patients then received infusion of related or unrelated donor peripheral blood progenitor cells on day 0. Patients also receive cyclosporine IV continuously beginning on day -2, continuing (IV or orally) until day 100, followed by a taper.","id":"BG000","title":"Preparative Regimen of Pentostatin and Alemtuzumab"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"}],"title":"<=18 years"},{"measurements":[{"groupId":"BG000","value":"11"}],"title":"Between 18 and 65 years"},{"measurements":[{"groupId":"BG000","value":"3"}],"title":">=65 years"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Age, Categorical","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"5"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"9"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}